Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided.

Key Features

KEY FEATURES: * One work that can be consulted for all aspects of anticancer drug development * Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts * A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death * Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products * Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques * Hundreds of references that allow the reader to access relevant scientific and medical literature * Clear illustrations, some in color, that provide both understanding of the field and material for teaching


Oncologists, cancer researchers, pharmacologists, molecular biologists, and cell biologists.

Table of Contents

Contributors Preface Chapter 1 A Brief History of Cancer Chemotherapy Summary 1. Introduction 2. Genotoxic (Cytotoxic) Therapy 3. Growth Control Pathways 4. Host–Tumor Interactions 5. Conclusions References Chapter 2 Novel Targets in the Cell Cycle and Cell Cycle Checkpoints Summary 1. Introduction 2. Molecular Regulation of Cell Cycle Progression 3. Molecular Regulation of Cell Cycle Checkpoints 4. Rationale for Targeting Cyclin-Dependent Kinases and Cell Cycle Checkpoint Pathways 5. Agents and Strategies for Therapeutic Interference 6. Conclusions References Chapter 3 Growth Factor and Signal Transduction Targets for Cancer Therapy Summary 1. Introduction 2. The ErbB Family of Receptor Tyrosine Kinases (RTKs) 3. The Ras-Raf-MEK-ERK Signaling Pathway 4. c-Src Kinase, Signal Transduction, Transformation, and Cancer 5. Akt 6. Nuclear Hormone Receptors as Targets for Cancer Therapy 7. Implications for Drug Discovery and Development References Chapter 4 Cell Death Pathways as Targets for Anticancer Drugs Summary 1. Introduction 2. Two Main Pathways for Drug-Induced Apoptosis 3. Modulation of Drug-Induced Cell Death by Bcl-2 and Related Proteins 4. The Central Role of Caspases in Drug-Induced Apoptosis 5. Synergy between Death Receptors and Cytotoxic Drugs 6. The Rel/NF-kB/IkB Proteins 7. Conclusion References Chapter 5 Drug Resistance Pathways as Targets Summary 1. Introduction 2. Targeting Drug Transport 3. Targeting Cellular Stress Responses 4. Targeting DNA Repair Systems 5. Conclusions References Chapter 6 Role of Matrix Metalloproteinases and Plasminogen Activators in Cancer Invasion and Metastasis: Therapeutic Strategies Summary 1. Introduction 2. The Extracell


No. of pages:
© 2002
Academic Press
eBook ISBN:
Print ISBN:
Print ISBN:

About the editors

Bruce Baguley

Affiliations and Expertise

The University of Auckland, New Zealand

David Kerr

Affiliations and Expertise

University of Oxford, United Kingdom


@qu:"..this is a really extensive and comprehensive book on the drug development process. ...There is very little overlap between chapters and all are written by experts in the field. Hundreds of useful references are included for those wanting to go further. ...Very good value...and essential reading for both the scientist and Ph.D. student. Definately one for the library to stock." @source:—Paul Loadman, University of Bradford, UK for BRITISH JOURNAL OF CANCER (2002) @qu:"Well-referenced and indexed...this text would be a useful addition to the clinic, research laboratory and institution library." @source:—P. Parsons, Queensland Institute of Medical Research for CANCER FORUM (2002)